Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radion-pdt
- Development stage
- Phase 2
- Lead developer
- Radionetics Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous, Topical, Oral (for Some Agents)
01
Overview
Radion-pdt appears to refer to a specific photodynamic therapy (PDT) drug or product, but there is no evidence in the available literature or clinical resources for a photosensitizer or pharmaceutical agent with this exact name. Photodynamic therapy (PDT) is a treatment that uses special drugs called photosensitizing agents, which are activated by light of a specific wavelength to produce reactive oxygen species that kill cancer cells. PDT can also damage tumor blood vessels and stimulate an immune response against tumor cells. The most widely used and FDA-approved PDT drugs include porfimer sodium (Photofrin) and aminolevulinic acid (ALA/Levulan), but "Radion-pdt" does not match any known approved or investigational agent in this class[1][2][3][6]. If "Radion-pdt" refers to a new, investigational, regional, or proprietary formulation of PDT not yet described in major databases as of June 2025, further details would be required for accurate classification.
- Brand names
- Radion-pdt
- Other names
- Radion-pdt
Beyond the preview
Go deeper on Radion-pdt.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radion-pdt.